Glycemic control and cardiovascular disease in chronic kidney disease

Area of Science:

• Nephrology
• Cardiology
• Endocrinology

Background:

• Diabetes is a major risk factor for cardiovascular (CV) disease, comparable to myocardial infarction.
• Advanced kidney disease (glomerular filtration rate < 60 mL/min) also significantly increases CV risk, even without diabetes.
• Diabetes is the leading cause of end-stage kidney disease requiring dialysis, creating a high-risk group for CV events.

Purpose of the Study:

• To review the current understanding of cardiovascular risk in patients with diabetes and kidney disease.
• To examine the role of glycemic control in mitigating cardiovascular risk within this specific patient population.
• To highlight the limited data and future research needs regarding glycemic control and kidney disease progression.

Main Methods:

• Review of epidemiologic data and secondary analyses of clinical trials, primarily in type 1 diabetes.
• Focus on studies examining cardiovascular outcomes in patients with co-existing diabetes and kidney disease.
• Analysis of associations between glycemic control levels (hemoglobin A1c) and adverse events.

Main Results:

• Failure to achieve reasonable glycemic control (hemoglobin A1c < 7.5%) is associated with increased risk of CV events and hospitalizations in advanced kidney disease.
• Data on glycemic control's impact on cardiovascular risk reduction in kidney disease patients are sparse.
• The link between poor glycemic control and kidney disease progression requires further investigation.

Conclusions:

• Patients with both diabetes and advanced kidney disease face the highest cardiovascular risk.
• Maintaining adequate glycemic control is crucial for reducing CV events and infections in this vulnerable group.
• Further research is essential to understand how glycemic control affects kidney disease progression.